Radiotherapy for solitary plasmacytoma of bone and soft tissue

Suh, Yang Gun; Suh, Chang Ok; Kim, Jin Seok; Kim, Soo Jeong; Pyun, Hae Ok; Cho, Jaeho

doi:10.1007/s00277-012-1510-6

Cited by 63 publications

(66 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its rarity, most of our knowledge derives from retrospective studies, which usually regard RT as the most effective therapy. After a moderate (40-50Gy) dose of radiation (Mendenhall et al, 1980;Mendenhall et al, 2003;Kilciksiz et al, 2008), a 5-year local control rate of 81-95% could be expected (Ozsahin et al, 2006;Sasaki et al, 2012;Suh et al, 2012). 5-year overall survival rate is reported to be 70-78% (Frassica et al, 1989;Reed et al, 2011;Suh et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…After a moderate (40-50Gy) dose of radiation (Mendenhall et al, 1980;Mendenhall et al, 2003;Kilciksiz et al, 2008), a 5-year local control rate of 81-95% could be expected (Ozsahin et al, 2006;Sasaki et al, 2012;Suh et al, 2012). 5-year overall survival rate is reported to be 70-78% (Frassica et al, 1989;Reed et al, 2011;Suh et al, 2012). 5-year MMFS ranges from 47 to 52% (Reed et al, 2011;Suh et al, 2012) and 5-year PFS from 43 to 56% (Frassica et al, 1989;Sasaki et al, 2012;Suh et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…5-year overall survival rate is reported to be 70-78% (Frassica et al, 1989;Reed et al, 2011;Suh et al, 2012). 5-year MMFS ranges from 47 to 52% (Reed et al, 2011;Suh et al, 2012) and 5-year PFS from 43 to 56% (Frassica et al, 1989;Sasaki et al, 2012;Suh et al, 2012). Similarly, in the current study, though various treatments were used, 5-year LPFS, MMFS, PFS and OS are 87.4%, 69.8%, 87.0% and 80.9%, respectively, comparable to previous studies.…”

Section: Discussionmentioning

confidence: 99%

“…SP responds well to local treatment. 10-year local control rate reaches to 81-95% (Chak et al, 1987;Tsang et al, 2001;Reed et al, 2011;Sasaki et al, 2012;Suh et al, 2012). Median survival time is reported to be 7-12 years (Knowling et al, 1983;Chak et al, 1987;Frassica et al, 1989;Liebross et al, 1998;Bachar et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…Median survival time is reported to be 7-12 years (Knowling et al, 1983;Chak et al, 1987;Frassica et al, 1989;Liebross et al, 1998;Bachar et al, 2008). However, in spite of a curative treatment, some cases progress to multiple myeloma (MM) eventually, approximately 60% in SBP (Bataille et al, 1981;Ozsahin et al, 2006;Reed et al, 2011) and 8-64% in EMP (Strojan et al, 2002;Ozsahin et al, 2006;Bachar et al, 2008;Reed et al, 2011;Suh et al, 2012). Once the disease becomes systemic, the prognosis is similar to patients initially diagnosed with MM, and 5-year OS decreases to 33% (Mendenhall et al, 1980).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

Li¹,

Niu²,

Wang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: A moderate dose of radiation is the recommended treatment for solitary plasmacytoma (SP), but there is controversy over the role of surgery. Our study aimed at comparing different treatment modalities in the management of SP. Materials and Methods: Data from 38 consecutive patients with solitary plasmacytoma, including 16 with bone plasmacytoma and 22 with extramedullary plasmacytoma, were retrospectively reviewed. 15 patients received radiotherapy alone; 11 received surgery alone, and 12 received both. The median radiation dose was 50Gy. All operations were performed as radical resections. Local progression-free survival (LPFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS) and overall survival (OS) were calculated and outcomes of different therapies were compared. Results: The median follow-up time was 55 months. 5-year LPFS, MMFS, PFS and OS were 87.0%, 80.9%, 69.8% and 87.4%, respectively. Univariate analysis revealed, compared with surgery alone, radiotherapy alone was associated with significantly higher 5-year LPFS (100% vs 69.3%, p=0.016), MMFS (100% vs 51.4%, p=0.006), PFS (100% vs 33.7%, p=0.0004) and OS (100% vs 70%, p=0.041). Conclusions: Radiotherapy alone can be considered as a more effective treatment for SP over surgery. Whether a combination of radiotherapy and surgery improves outcomes requires further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

Li¹,

Niu²,

Wang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Katodritou¹,

Terpos

Symeonidis

et al. 2014

American J Hematol

View full text Add to dashboard Cite

Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice is local radiotherapy (R/T) 6 surgical excision. The role of adjuvant chemotherapy (C/T) or novel agents (NA) is uncertain. Data related to prognostic factors are inconclusive. Herein, we describe the clinical features, survival and prognosis of 97 consecutive patients, 65 with bone SP (SBP), and 32 with extramedullary SP (SEP), diagnosed and treated in 12 Greek Myeloma Centers. Objective response rate (PR) and complete response (CR) was 91.8% and 61.9%, respectively, and did not differ between the 2 groups. Overall, 38 patients relapsed or progressed to multiple myeloma (MM). After a median follow-up of 60 months, 5 and 10-year overall survival (OS) probability was 92% and 89% in SEP and 86% and 69% in SBP, respectively (P 5 0.2). The 5-and 10-year MMfree survival (MMFS) probability was 90% and 70% for patients with SEP vs. 59% and 50% for patients with SBP, respectively (P 5 0.054). Overall, the 5-and 10-year OS probability, plasmacytoma relapse-free survival (PRFS), progression-free survival and MMFS was 84% and 78%, 72% and 58%, 58% and 43%, and 70% and 59%, respectively. In the multivariate analysis, prolonged PRFS and young age were positive predictors of OS. Achievement of CR was the only positive predictor of PRFS. Immunoparesis was the only negative predictor of progression to MM. The addition of C/T or NA-based treatment increased toxicity without offering any survival advantage over R/T.

show abstract

Solitary extraosseous plasmacytoma

Merza

Sarkar

2016

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessagePlasma cell neoplasms are characterized by a neoplastic plasma cell lineage which produces a monoclonal immunoglobulin. These neoplasms can present as a single lesion (solitary plasmacytoma) or as multiple lesions (multiple myeloma). Solitary plasmacytomas most frequently occur in bone (plasmacytomas of bone), but can also be found outside bone in soft tissues (extramedullary plasmacytomas).

show abstract

Radiotherapy for solitary plasmacytoma of bone and soft tissue

Cited by 63 publications

References 27 publications

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Solitary extraosseous plasmacytoma

Contact Info

Product

Resources

About